Cargando…
Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children
Infants and children under five years of age are the most vulnerable to malaria with over 1,700 deaths per day from malaria in this group. However, until recently, there were no WHO-endorsed paediatric anti-malarial formulations available. Artemisinin-based combination therapy is the current standar...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760242/ https://www.ncbi.nlm.nih.gov/pubmed/19818174 http://dx.doi.org/10.1186/1475-2875-8-S1-S7 |